Exploiting research at University of Pittsburgh and UPMC, Novasenta has been established with $20m in seed financing.

Novasenta, a US-based developer of cancer treatments, has been formed with $20m in seed capital to advance research at University of Pittsburgh (Pitt) and its health system affiliate, UPMC. UPMC Enterprises, the innovation arm of UPMC, contributed to the seed round. No other investors were identified. Founded in 2018, Novasenta is working on immunotherapies targeting…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.